jRCT2031230109Recruiting
Untitled Trial
EMBER 4: A Randomized, Open Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2 Early Breast Cancer With an Increased Risk of Recurrence (J2J MC JZLH)
Eli Lilly Japan K.K.Japan Registry Clinical Trial
VerifiedJapan Registry Clinical Trial
Study focus
- Disease/Condition
- Breast Neoplasms
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Eli Lilly Japan K.K.
- Location
- Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech;Finland;France;Germany;Greece;China;Hu
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
ICD-10 classifications
Malignant neoplasm of breastMalignant neoplasm of breastMalignant neoplasm: Breast, unspecifiedBenign neoplasm of breastMalignant neoplasm: Central portion of breast
Data source
- Registry
- Japan Registry Clinical Trial
- Trial ID
- jRCT2031230109
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for jRCT2031230109 through Pure Global AI's free database. This phase not specified trial is sponsored by Eli Lilly Japan K.K. and is currently Recruiting. The study focuses on Breast Neoplasms.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Japan Registry Clinical Trial data, helping medical device and pharmaceutical companies navigate clinical research efficiently.